Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and adult toys.
Popular Articles

Simulating The Pandemic Disease Airport Screening System
Four major US national laboratories have worked together to develop a computer model to help airport authorities screen passengers for pandemic influenza. The tool can help estimate false negatives, people with influenza who slip through the screening process, and so assess the risk of infected passengers unknowingly spreading disease across the nation.
buy viagra
Patient Upside Murky In Drug-Price Cases
"The prices of hundreds of brand-name drugs are about to be cut 4%, and millions of Americans may soon receive a check in the mail as compensation for having overpaid for their prescriptions," but "the extent to which the average consumer will benefit isn"t yet clear," the Wall Street Journal reports. "The price cuts and expected payments are the result of federal class-action settlements involving two drug-price publishers and a major drug wholesaler that were accused of inflating drug prices."
News of the day
Two-thirds Of Publicly-insured Adults Have One Or More Chronic Conditions
Nearly two of every three adult Americans under age 65 who were covered by public insurance from 2005 to 2006 had at least one chronic illness, such as diabetes, heart disease, and kidney disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Diagnostics

FDA Accepts CyDex Pharmaceuticals' IND Application For Oncology Drug

CyDex Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company"s Investigational New Drug (IND) application for a clinical study of Captisol-Enabled® melphalan HCL (CDX-353). Melphalan is an FDA-approved low dose chemotherapy for multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline. In December 2008, CyDex received orphan-drug designation from the FDA for melphalan "as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation." This designation provides an important economic incentive, granting CyDex seven years of exclusive marketing rights. "IND acceptance for Captisol-enabled melphalan is an important milestone for CyDex as we work to develop a portfolio of new drugs for the hospital acute care market," said Theron E. Odlaug, CyDex"s president and chief executive officer. "We look forward to establishing a relationship with a strategic out-licensing partner to advance CDX-353 into the clinic and, longer-term, develop and commercialize this promising oncology product." Upcoming clinical studies are expected to begin with a phase 2(a) trial that compares the pharmacokinetics of CyDex"s CDX-353: Propylene Glycol-Free Melphalan HCL with Alkeran, and evaluate safety parameters. Alkeran is packaged as two separate vials that must be combined prior to injection and, due to its limited stability, administered immediately thereafter. CyDex"s version of melphalan is enabled by Captisol®, the company"s proprietary and patented sulfobutylether í²-cyclodextrin. Captisol-Enabled® melphalan is a one-vial formulation that does not contain harsh co-solvents and remains stable at room temperature for an extended period of time. "CDX-353 is a novel form of melphalan that is more stable and could potentially allow for longer administration durations and slower infusion rates compared to current pre-transplant treatments for multiple myeloma," said Parameswaran Hari, M.D., Clinical Director of the Adult Bone Marrow Transplant Program and Associate Professor of Medicine at the Medical College of Wisconsin. "These advantages have the potential to enable doctors to safely achieve a higher dose intensity of pre-transplant chemotherapy, which could lead to better therapeutic outcomes." CyDex Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009